Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yeda Research And Devlopment Co. Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is concentrated under 1 distinct examiner, which simplifies the communication channel for the company's legal representatives. The prosecution is further limited to 1 distinct art unit, reflecting a specific technical focus within the broader pharmaceutical sector. Such a focused portfolio allows for a very specific prosecution approach, as the company is not managing competing requirements from different examiners at this time.
The busiest examiner identified in the data is CHICKS, ASHLI ARIANA, who holds 1 busiest examiner pending action. This single action accounts for the total of 1 pending office action currently facing the portfolio. Practitioners should note that with only 1 distinct examiner and 1 distinct art unit involved, there is no internal baseline for comparing examiner behavior or art unit speed within this specific set of filings. The success of the Biotechnology & Pharmaceuticals strategy currently hinges on the interaction with CHICKS, ASHLI ARIANA, requiring a tailored approach to this specific official's requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | CHICKS, ASHLI ARIANA | 54d |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | 54d | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial